NCT02741258 is a Phase 3 clinical trial of Mepitel Film in Post-surgery Radiotherapy, sponsored by Dario Valcarenghi.

Who is sponsoring NCT02741258?

NCT02741258 is sponsored by Dario Valcarenghi.

What drugs are being tested in NCT02741258?

Interventions in NCT02741258: Mepitel Film, skin cream.

What condition does NCT02741258 study?

NCT02741258 studies Post-surgery Radiotherapy.

Is NCT02741258 still recruiting?

NCT02741258 is currently completed. Last updated 5 July 2022.

Last reviewed 2022-07-05 · How we verify

NCT02741258

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mepitel Film Treatment for the Prevention and Cutaneous Toxicity Due to Radiotherapy

Completed Phase 3 Last updated 5 July 2022

What this trial tests

Phase 3 trial testing Mepitel Film in Post-surgery Radiotherapy in 164 participants. Completed in 31 December 2021.

Timeline

1 October 2015

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Dario Valcarenghi
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	164
Start date	1 October 2015
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	2 locations across Switzerland

Drugs / interventions tested

Mepitel Film
skin cream — full drug profile →

Conditions studied

Post-surgery Radiotherapy — all drugs for Post-surgery Radiotherapy →

Sponsor

Dario Valcarenghi — full company profile →

Who can join

18 and older, female only, with Post-surgery Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized study, mepitel vs standard of care for the prevention and skin toxicity due to radiotherapy in patients with post-surgery breast cancer. Mepitel film will be placed on the skin of the patients just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of toxicities.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mepitel® film versus standard care for the prevention of skin toxicity in breast cancer patients treated with adjuvant radiotherapy: A randomized controlled trial.
Valcarenghi D, Tolotti A, Vees H, Torri V, et al · · 2025 · cited 1× · PMID 40110362 · DOI 10.1016/j.ctro.2025.100936

Verify or expand the search:

Other trials of Mepitel Film

Trials testing the same drug.

NCT03910595 — Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients · NA · completed
NCT06133218 — Patient Reported Outcomes Using Mepitel Film During Radiotherapy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02741258 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dario Valcarenghi
Last refreshed: 5 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02741258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing